$2.27 Billion is the total value of Ikarian Capital, LLC's 230 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR THERAPEUTICS AGput | $17,654,000 | +83.1% | 115,300 | 0.0% | 0.78% | +11.5% | |
| DCPH | DECIPHERA PHARMACEUTICALS INcall | $7,989,000 | +11.2% | 140,000 | 0.0% | 0.35% | -32.3% | |
| IMAB | I MABsponsored ads | $7,073,000 | +0.3% | 150,000 | 0.0% | 0.31% | -38.8% | |
| BTAI | BIOXCEL THERAPEUTICS INCcall | $6,930,000 | +6.5% | 150,000 | 0.0% | 0.31% | -35.0% | |
| IMTX | IMMATICS N.V | $6,885,000 | +1.7% | 638,094 | 0.0% | 0.30% | -38.0% | |
| ALNY | ALNYLAM PHARMACEUTICALS INCput | $6,499,000 | -10.7% | 50,000 | 0.0% | 0.29% | -45.5% | |
| SLDB | SOLID BIOSCIENCES INC | $5,973,000 | +273.3% | 788,008 | 0.0% | 0.26% | +126.7% | |
| CHAQU | CHARDAN HEALTHCR ACQSTN 2 COunit 99/99/9999 | $4,236,000 | +0.4% | 400,000 | 0.0% | 0.19% | -38.7% | |
| DMAC | DIAMEDICA THERAPEUTICS INC | $4,208,000 | +139.2% | 415,000 | 0.0% | 0.19% | +46.5% | |
| CARA | CARA THERAPEUTICS INC | $4,137,000 | +18.8% | 273,524 | 0.0% | 0.18% | -27.8% | |
| KDMN | KADMON HLDGS INC | $3,887,000 | +5.8% | 936,615 | 0.0% | 0.17% | -35.7% | |
| XENE | XENON PHARMACEUTICALS INC | $3,432,000 | +38.9% | 223,173 | 0.0% | 0.15% | -15.6% | |
| ITCI | INTRA CELLULAR THERAPIES INCput | $3,180,000 | +23.9% | 100,000 | 0.0% | 0.14% | -24.7% | |
| AGEN | AGENUS INC | $3,020,000 | -20.5% | 950,000 | 0.0% | 0.13% | -51.6% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $2,995,000 | +29.7% | 56,008 | 0.0% | 0.13% | -21.0% | |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $2,630,000 | -6.4% | 23,654 | 0.0% | 0.12% | -42.9% | |
| NKTR | NEKTAR THERAPEUTICScall | $2,550,000 | +2.5% | 150,000 | 0.0% | 0.11% | -37.8% | |
| ACHIEVE LIFE SCIENCES INC | $2,302,000 | -3.2% | 284,151 | 0.0% | 0.10% | -41.3% | ||
| AGTC | APPLIED GENETIC TECHNOLOGIES | $2,232,000 | -15.9% | 545,884 | 0.0% | 0.10% | -49.0% | |
| NXTC | NEXTCURE INC | $2,179,000 | +23.8% | 200,000 | 0.0% | 0.10% | -24.4% | |
| AUPH | AURINIA PHARMACEUTICALS INCcall | $1,383,000 | -6.2% | 100,000 | 0.0% | 0.06% | -43.0% | |
| IFRX | INFLARX NV | $754,000 | +18.4% | 149,750 | 0.0% | 0.03% | -28.3% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $563,000 | +1.6% | 54,901 | 0.0% | 0.02% | -37.5% | |
| CERC | CERECOR INC | $536,000 | +16.5% | 202,865 | 0.0% | 0.02% | -27.3% | |
| ABUS | ARBUTUS BIOPHARMA CORP | $408,000 | +13.3% | 115,000 | 0.0% | 0.02% | -30.8% | |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $366,000 | +33.1% | 54,694 | 0.0% | 0.02% | -20.0% | |
| RAPT | RAPT THERAPEUTICS INCput | $309,000 | -38.6% | 15,600 | 0.0% | 0.01% | -61.1% | |
| BLU | BELLUS HEALTH INC NEW | $306,000 | +34.8% | 100,000 | 0.0% | 0.01% | -18.8% | |
| MLND | MILLENDO THERAPEUTICS INC | $289,000 | +31.4% | 135,193 | 0.0% | 0.01% | -18.8% | |
| NVAX | NOVAVAX INC | $294,000 | +2.8% | 2,636 | 0.0% | 0.01% | -38.1% | |
| IVA | INVENTIVA SAads | $214,000 | +20.9% | 15,000 | 0.0% | 0.01% | -30.8% | |
| BXRX | BAUDAX BIO INC | $101,000 | -63.5% | 100,000 | 0.0% | 0.00% | -80.0% | |
| GBT | GLOBAL BLOOD THERAPEUTICS INput | $91,000 | -22.2% | 2,100 | 0.0% | 0.00% | -50.0% | |
| MITO | STEALTH BIOTHERAPEUTICS CORPsponsored ads | $57,000 | +14.0% | 37,597 | 0.0% | 0.00% | -25.0% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $60,000 | +46.3% | 4,739 | 0.0% | 0.00% | 0.0% | |
| APTOSE BIOSCIENCES INC | $18,000 | -21.7% | 3,904 | 0.0% | 0.00% | -50.0% | ||
| CCXI | CHEMOCENTRYX INC | $2,000 | +100.0% | 37 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.